Pain and neuropathic pain measures for baseline and final visit stratified on vitamin D status with significance at each visit
| Baseline vitamin D status | Total McGill pain location Median (IQR) (–/45) | McGill pain score Median (IQR) (–/5) | DN4 Median (IQR) (–/10) | Positive symptoms (DN4) Median (IQR) (–/6) | ||||
|---|---|---|---|---|---|---|---|---|
| Pretreatment baseline | V5 | Pretreatment baseline | V5 | Pretreatment baseline | V5 | Pretreatment baseline | V5 | |
| <30 ng/mL (n=80) | 21.9±15.0 23.5 (6–37) | 6.2±6.3* 5 (3–8) | 2.0±0.9 2 (1–3) | 1.5±1.0** 1.5 (1–2) | 2.8±1.8 3 (1–4) | 2.8±2.0 3 (1–4) | 1.9±1.5 2 (1–3) | 1.4±1.2ª 1 (0–2) |
| ≥30 ng/mL (n=63) | 20.6±15.1 19 (7–36) | 5.6±3.8* 5 (3–8) | 2.2±1.0 2 (2–3) | 1.6±0.9σ 1 (1–2) | 3.3±1.7 3 (2–4) | 3.1±1.8 3 (2–4) | 2.1±1.4 2 (1–3) | 1.4±1.1** 1 (0–2) |
*p<0.0001, **p=0.002, ªp=0.05, σp=0.0002.
DN4, Douleur Neuropathique 4.